However, within patients with features of aHUS (i.e., TMA patients with renal failure, a detectable ADAMTS13 activity and no associated STEC), distinct diseases with specific pathophysiological mechanisms, therapeutic modalities and prognosis may be further individualized. This evidence concerns the gene ADAMTS13 and acute kidney injury.